Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : xoma -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (1)	2/16/2000 11:34:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 5

xoma desperates for money during the biotech craze. PDLI, much less future than xoma, except for ideal future on genomics (like everybody, but AFFX, no products), and at $200 a share the market cap of $3B! (xoma should go 9x6 to $54 following the same market perception). It is a low tier deal considering xoma's prospects are so good, so near, and so real. Baxter and DNA deals should be able to get the company across one year cash, now xeoperson wants two year cash! He does not want a "surprise" at the FDA, cash first. Many predicted the biotech boom, but not the date and time. But xoma does not have any genomics, maybe they should called xoma a proteomics company (the next craze building up), bpi, hu1124, geminmune, and fusion and even thaumatin are proteins!